Homeβ€ΊCliniciansβ€ΊHepatitis B Serology Interpreter

Hepatitis B Serology Interpreter

Select the patient's three-marker Hepatitis B serology result. The interpretation, clinical context, and next steps update automatically. Aligned with ASHM B Positive: Hepatitis B Guide for Primary Care (4th edition).

πŸ“‹ Sources: ASHM — B Positive: Hepatitis B Guide for Primary Care (4th edition); ASHM — Decision Making in Hepatitis B; GESA Australian Consensus Recommendations for HBV; Australian Immunisation Handbook — Hepatitis B; National HBV Testing Policy. Verified June 2026.
Educational reference for clinicians, not patient-specific advice. Use clinical judgement; chronic HBV management often requires s100-accredited prescriber or specialist input.
⚠ Use clinical judgement. Lab assays vary — pattern interpretation can be confounded by recent vaccination, window periods, or false positives. Repeat indeterminate panels. Anti-HBs <10 mIU/mL is considered non-immune. Australia: 24.5% of people living with chronic HBV are currently engaged in care (target 50%) — if you find a positive result, engaging the patient in monitoring matters.

Select results

HBsAgHepatitis B surface antigen
anti-HBcTotal core antibody
anti-HBsSurface antibody
All eight standard patterns β€” reference table
HBsAganti-HBcanti-HBsInterpretation
βˆ’βˆ’βˆ’Susceptible (no immunity, no infection). Vaccinate.
βˆ’βˆ’+Vaccinated (immunity from vaccine).
βˆ’++Past resolved infection (natural immunity).
βˆ’+βˆ’Isolated anti-HBc β€” repeat & investigate.
++βˆ’Active infection (acute vs chronic β€” check anti-HBc IgM).
+++Unusual β€” recheck; sometimes seen during seroconversion.
+βˆ’βˆ’Very early acute (window) or false positive β€” repeat.
+βˆ’+Very unusual β€” repeat & consult.
Phase classifier β€” chronic HBV

When chronic infection is confirmed (HBsAg + for > 6 months), the phase guides monitoring and treatment. Enter the four phase markers below for the classification, the monitor-vs-treat decision, and referral guidance.

HBeAge-antigen
HBV DNAviral load (IU/mL)
ALTvs upper limit normal
FibrosisFibroScan / APRI / FIB-4
Full phase reference table
Phase HBeAg HBV DNA ALT Action
HBeAg-positive infection
(immune tolerant)
+Very high (typically >10⁷)NormalMonitor 6-monthly. No treatment.
HBeAg-positive hepatitis
(immune clearance)
+ElevatedElevatedTreat β€” refer to s100 prescriber or specialist.
HBeAg-negative infection
(inactive carrier)
βˆ’ / anti-HBe +Low (<2,000 IU/mL)NormalMonitor 6-monthly. Confirm stable phase over time.
HBeAg-negative hepatitis
(reactivation)
βˆ’Elevated (>2,000 IU/mL)ElevatedTreat β€” refer to s100 prescriber or specialist.
Occult HBV
(HBsAg-negative phase)
βˆ’Detectable (low)NormalMonitor; risk of reactivation if immunosuppressed.

All people with chronic HBV need 6-monthly monitoring (ALT, HBV DNA, Β± AFP/USS if HCC surveillance indicated). HCC surveillance criteria: Asian-born males >40, Asian-born females >50, Aboriginal & Torres Strait Islander people >50, African-born >20, family history of HCC, or cirrhosis at any age.

Who to test in primary care
  • People born in countries with HBV prevalence β‰₯2% (most of Asia, Africa, Pacific Islands, parts of Eastern Europe / South America)
  • Aboriginal and Torres Strait Islander people
  • Household and sexual contacts of people with HBV
  • People who inject drugs (current or past)
  • Men who have sex with men
  • People living with HIV or HCV
  • People with elevated ALT of unknown cause
  • Pregnant women (universal antenatal screening)
  • Before chemotherapy, immunosuppression (especially anti-CD20 / rituximab), biologics, or transplant
  • Anyone requesting testing

Order the three-marker panel together: HBsAg + anti-HBc + anti-HBs. This single combined test gives you the full picture in one go.

Treating chronic HBV β€” s100 pathway
Antiviral treatment of CHB (tenofovir disoproxil, tenofovir alafenamide, entecavir) is funded through Section 100 (s100). Only accredited s100 prescribers can initiate. Pathway options for primary care:
  • Refer to a community s100-accredited GP, hepatologist, or infectious diseases physician
  • Refer to a tertiary liver clinic (mandatory if cirrhosis is present)
  • Become s100 accredited yourself — ASHM's National Hepatitis B Advanced Management and Prescribing course (RACGP / ACRRM CPD-accredited, free)
  • Maintenance prescribing of an established regimen does NOT require s100 accreditation in most jurisdictions — verify locally
Clinical support β€” phone-a-friend
Australian Centre for Disease Control HepLink
Free, gov-funded line for clinical and patient support across all hepatitis. Mon–Fri 9am–5pm.
1800 437 222 (1800 HEP ABC)
HepBhelp
Online portal for Australian GPs needing further investigation/management advice on chronic HBV.
hepbhelp.org.au
B Positive Guide (4th ed)
ASHM's flagship primary-care reference for chronic hepatitis B β€” free online.
hepatitisb.org.au

You might also like

πŸ’‰
Adult Vaccination Checker
Eligibility for HBV catch-up and other adult vaccines, by risk group.
πŸ§ͺ
CKD Stage Calculator
Tenofovir requires renal dose-adjustment β€” confirm eGFR before initiating.
πŸ“‹
Vaccination Catch-up
HBV catch-up schedules for adults found non-immune.